IN2015DN03075A - - Google Patents

Info

Publication number
IN2015DN03075A
IN2015DN03075A IN3075DEN2015A IN2015DN03075A IN 2015DN03075 A IN2015DN03075 A IN 2015DN03075A IN 3075DEN2015 A IN3075DEN2015 A IN 3075DEN2015A IN 2015DN03075 A IN2015DN03075 A IN 2015DN03075A
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Tillmann; Taube
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of IN2015DN03075A publication Critical patent/IN2015DN03075A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
IN3075DEN2015 2012-11-30 2015-04-13 IN2015DN03075A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12195162 2012-11-30
PCT/EP2013/074862 WO2014083058A1 (en) 2012-11-30 2013-11-27 Combination therapy with volasertib

Publications (1)

Publication Number Publication Date
IN2015DN03075A true IN2015DN03075A (enExample) 2015-10-02

Family

ID=47325907

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3075DEN2015 IN2015DN03075A (enExample) 2012-11-30 2015-04-13

Country Status (15)

Country Link
US (2) US20140154304A1 (enExample)
EP (1) EP2925343A1 (enExample)
JP (1) JP2016501208A (enExample)
KR (1) KR20150090091A (enExample)
CN (1) CN104812400A (enExample)
AU (1) AU2013351180A1 (enExample)
BR (1) BR112015011748A2 (enExample)
CA (1) CA2889787A1 (enExample)
CL (1) CL2015001258A1 (enExample)
EA (1) EA201500579A1 (enExample)
IL (1) IL238174A0 (enExample)
IN (1) IN2015DN03075A (enExample)
MX (1) MX2015006592A (enExample)
PH (1) PH12015501113A1 (enExample)
WO (1) WO2014083058A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9867831B2 (en) * 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
CN104306336B (zh) * 2014-11-18 2016-08-24 河北天成药业股份有限公司 枸橼酸柔红霉素脂质体注射液的制备工艺
CA3219061A1 (en) * 2015-11-11 2017-05-18 Celator Pharmaceuticals, Inc. Assays and methods for selecting a treatment regimen for a subject with leukemia
WO2021242859A1 (en) * 2020-05-27 2021-12-02 Duke University Compositions and methods for sensitizing acute myeloid leukemias to chemotherapy
CN116785296B (zh) * 2023-06-06 2025-09-05 河北渤腾医药技术有限公司 一种plk1的抑制剂及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076454A1 (de) 2003-02-26 2004-09-10 Boehringer Ingelheim Pharma Gmbh & Co Kg Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
WO2008074572A1 (en) * 2006-12-20 2008-06-26 Universitätsklinikum Hamburg-Eppendorf Use of tri-substituted glycerol compounds for the treatment of hematological malignancies
SI3300601T1 (sl) * 2007-02-16 2022-05-31 Rotalec Ip Holdings Llc Fiksna razmerja med zdravili za zdravljenje vrst hematopoetskega raka in proliferativnih motenj
US9358233B2 (en) * 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia

Also Published As

Publication number Publication date
KR20150090091A (ko) 2015-08-05
EA201500579A1 (ru) 2015-12-30
MX2015006592A (es) 2015-08-05
CN104812400A (zh) 2015-07-29
JP2016501208A (ja) 2016-01-18
US20170173023A1 (en) 2017-06-22
WO2014083058A1 (en) 2014-06-05
PH12015501113A1 (en) 2015-08-17
US20140154304A1 (en) 2014-06-05
AU2013351180A1 (en) 2015-04-30
CL2015001258A1 (es) 2015-10-02
EP2925343A1 (en) 2015-10-07
IL238174A0 (en) 2015-05-31
BR112015011748A2 (pt) 2017-07-11
CA2889787A1 (en) 2014-06-05

Similar Documents

Publication Publication Date Title
BR112014017635A2 (enExample)
BR112014019107A2 (enExample)
BR112014017659A2 (enExample)
BR112014017592A2 (enExample)
BR112014017646A2 (enExample)
BR112014017638A2 (enExample)
BR112013027865A2 (enExample)
BR112014018344A2 (enExample)
BR112014017737A2 (enExample)
BR112014017634A2 (enExample)
BR112014017644A2 (enExample)
BR112014017588A2 (enExample)
BR112014017647A2 (enExample)
BR112014013184A8 (enExample)
BR112014018925A2 (enExample)
BR112014017652A2 (enExample)
BR112014017630A2 (enExample)
BR112014017627A2 (enExample)
BR112014018793A2 (enExample)
BR112014017631A2 (enExample)
BR112014017641A2 (enExample)
BR112014017589A2 (enExample)
BR112014017671A2 (enExample)
BR112014017636A2 (enExample)
BR112014017667A2 (enExample)